Aquestive Therapeutics Inc revenue growth has been varied year-over-year.

What is AQST's revenue growth rate?

Historical revenue data is available for Aquestive Therapeutics Inc to analyze growth trends.

How fast is AQST earnings growing?

Earnings growth data is available for Aquestive Therapeutics Inc analysis.

What is AQST's profit margin?

Profit margin data is available for Aquestive Therapeutics Inc.

AQST Revenue & Earnings Growth Analysis 2026 - Is Aquestive Therapeutics Inc Growing?

Growth Summary

Aquestive Therapeutics Inc (AQST) has experienced challenges in growth. The company operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.

Over the past 4 years, Aquestive Therapeutics Inc has achieved a revenue compound annual growth rate (CAGR) of 68.4%, while earnings have grown at 21.3% CAGR.

Latest Revenue

$57.56M

Net Income

$-44137000.00

5-Year Revenue CAGR

68.4%

4 years of data

Net Margin

N/A

Latest period

Revenue Growth Over Time

Historical revenue and profitability trends for Aquestive Therapeutics Inc

The chart above illustrates Aquestive Therapeutics Inc's revenue trajectory over the past 4 years. The revenue pattern shows the challenges the company has faced in recent periods.

Year-over-Year Growth Rates

Annual percentage change in revenue and earnings

Growth rates provide insight into the momentum of Aquestive Therapeutics Inc's business.

Profit Margin Trends

How efficiently Aquestive Therapeutics Inc converts revenue into profit

Understanding Profit Margins

Profit margins reveal how much of each dollar of revenue Aquestive Therapeutics Inc retains at different stages:

Gross Margin (N/A%): What remains after direct production costs
Operating Margin (N/A%): Profit from core operations before interest and taxes
Net Margin (N/A%): Final profit after all expenses

Future Growth Outlook

Analyst estimates and forward-looking indicators

EPS Estimate 2026

$-0.46

Current: $-0.51

EPS Estimate 2027

$-0.58

26.1% expected growth

Price Target

$8.89

Analyst consensus

What Analysts Are Saying

Wall Street analysts project Aquestive Therapeutics Inc to continue focusing on sustainable operations. The consensus analyst rating is 4.5556 based on 9 analysts.

Growth Analysis Conclusion

Based on our comprehensive analysis, Aquestive Therapeutics Inc (AQST) demonstrates declining growth characteristics.

Key Takeaways:

Revenue Growth:, 68.4% CAGR over 4 years
Profitability: shows the company is investing in growth over short-term profits
Efficiency:

Investment Considerations

This growth analysis provides a comprehensive view of Aquestive Therapeutics Inc's historical performance and future outlook. Investors should consider these growth metrics alongside valuation, competitive positioning, and broader market conditions when making investment decisions. Past performance does not guarantee future results.